Aim. To study the frequency, prescription patterns and extent of real consumption of pharmaceutical products for the treatment of  deep venous thrombosis (DVT) and estimate the effectiveness of  achievement of hypocoagulation based on the results of laboratory tests. Material and methods. This work was designed as an one-step descriptive pharmaco-epidemiological study based at the municipal hospitals of Volgograd. The structure of prescription of pharmaceutical products was characterized by means of frequency analysis. The real consumption of pharmaceutical agents was assessed using the ATC/DDD methodology as recommended by WHO. Results. The frequency analysis has demonstrated that anticoagulation therapy was prescribed to 91% of the patients, non-fractionated heparin (NFH) to 84% of them, and low-molecular weight heparin (LMWH) to 6.5%. Activated partial thromboplastin time (APTT) was determine in 36% of the patients given NFH. The real consumption of  parenteral anticoagulants was estimated at 71.95 DDD per 100 patient-days and 20.4 NDDD per 100 patient-days for NFH and LMWH respectively. Warfarin was prescribed to 75.5% of the patients. International normalized ratio (INR) was determined in 97% of these patients. Only 28% of the patients fell into the (2.0—3.0) therapeutic corridor. Average multiplicity of measurements per patient was 2.32 times. Warfarin consumption was estimated at 36.9 NDDD per 100 patient-days. The DU90% segment of  consumption of pharmaceutical products was in agreement with the list of vitally necessary and most essential medicines at the time of performance of the present pharmaco-epidemiological study. Conclusion. The results of the study indicate that the currently prescribed anticoagulation therapy of deep venous thrombosis under real clinical conditions not infrequently fails to produce the desired beneficial effects. The prescription of NFH and warfarin at low doses, inadequate monitoring of hypocoagulation, and the absence of dose correction depending on the results of laboratory tests are the main causes for which the optimal «therapeutic» hypocoagulation range necessary to ensure the maximum effectiveness and safety of the anticoagulation treatment can not be achieved.